Prosecution Insights
Last updated: October 04, 2026
Application No. 18/885,921

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME

Non-Final OA §101§102§112
Filed
Sep 16, 2024
Priority
Aug 01, 2008 — provisional 61/085,597 +6 more
Examiner
SEAMAN, D MARGARET M
Art Unit
Tech Center
Assignee
Chiesi Farmaceutici S.p.a.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
1075 granted / 1405 resolved
+16.5% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
46 currently pending
Career history
1424
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
35.8%
-4.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1405 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 34 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The claim as written should depend from a claim. However, the claim number is missing from the claim language. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 29-46 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claims are seemingly drawn to more than one statutory subject matter. The claims are initially drawn to a composition (clevidipine, soybean oil, emulsifier and water) but then appear to be drawn to a method involving time and preparation “wherein after storage for at least 36 months at about 2C-8C, the emulsion is stable”. The claims need to be drawn to one statutory subject matter and not two. Correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language. Claims 29-46 are rejected under pre-AIA 35 U.S.C. 102b as being anticipated by US Pat 5739152 Andersson. Andersson teaches a composition that is an emulsion containing a dihydropyridine compound (clevidipine), a lipid phase (soybean oil), emulsifier and water (see abstract). Col 6 lines 40-55 have specific examples which have compound C (Clevidipine), soybean oil, egg lecithin water and glycerol. Paragraph 59 teaches that the emulsion may also contain other solubility enhancers, antioxidants, stabilizers, pH-adjusting agents or tonicity modifying agents. Paragraph 64 taches that the pH may be adjusted. This anticipates the instant claims. Claims 29-46 are rejected under pre-AIA 35 U.S.C. 102(e) as being anticipated by Motheram US Patents 8658676, 10010537 & 11103490. All three patents teach a composition of clevidipine (claim 1 676), soybean oil (claim 2 676), emulsifier and water (claim 1 676). pH is 6-8 (claim 6 676). Emulsifier can be egg yolk (claim 4 676). Further comprising antioxidants (claim 5 676). Co emulsifiers (claim 7 676) of poloxamers, poloxamines, polyoyethylene sorbitan fatty acid esters, sorbitan fatty acid esters cholic acid and deoxycholic acid. These all anticipate the instant claims. The applied reference has a common inventor with the instant application. Based upon the pre-AIA 35 U.S.C. 102(e) date of the reference, it constitutes prior art. This rejection under pre-AIA 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor or joint inventors (i.e., the inventive entity) of this application and is thus not the invention “by another,” or if the same invention is not being claimed, by an appropriate showing under 37 CFR 1.131(a). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Sep 16, 2024
Application Filed
Sep 04, 2026
Non-Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747211
METHODS OF MAKING NICOTINIC ACID DERIVATIVES
3y 5m to grant Granted Sep 29, 2026
Patent 12741939
COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES
3y 6m to grant Granted Sep 22, 2026
Patent 12741937
A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN
3y 3m to grant Granted Sep 22, 2026
Patent 12692235
FUSED RING COMPOUND AND APPLICATION THEREOF
4y 0m to grant Granted Jul 28, 2026
Patent 12692276
TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
84%
With Interview (+8.0%)
2y 2m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1405 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month